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One Sentence Summary: Positron emission tomography identified tau pathology 
following a single traumatic brain injury. 
 
 
 
Abstract: Traumatic brain injury (TBI) can trigger progressive neurodegeneration, with 
tau pathology seen years after a single moderate-severe TBI. Identifying this type of post-
traumatic pathology in vivo might help to understand the role of tau pathology in TBI 
pathophysiology.  We used flortaucipir positron emission tomography (PET) to investigate 
whether tau pathology is present many years after a single TBI in humans. We examined 
PET data in relation to markers of neurodegeneration in the cerebrospinal fluid (CSF), 
structural magnetic resonance imaging (MRI) measures and cognitive performance. 
Cerebral flortaucipir binding was variable, with many participants with TBI showing 
increases in cortical and white matter regions. At the group level, flortaucipir binding was 
increased in the right occipital cortex in TBI when compared to healthy controls. 
Flortaucipir binding was associated with increased total tau, phosphorylated tau and 
ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) CSF concentrations, as well as with 
reduced fractional anisotropy and white matter tissue density in TBI. Apolipoprotein E 
(APOE) ε4 genotype a the relationship between flortaucipir binding and time since injury, 
CSF β-amyloid 1-42 (Aβ42) concentration, white matter tissue density and longitudinal 
mini-mental state examination (MMSE) scores in TBI. The results demonstrate that tau 
PET is a promising approach to investigating progressive neurodegeneration associated 
with tauopathy following TBI. 
 
 
 
  
Introduction 
Traumatic brain injury (TBI) can lead to chronic neurodegeneration and dementia 
in later life (1, 2). Deposition of hyperphosphorylated protein tau neurofibrillary tangles is 
a pathological hallmark of this neurodegenerative process (3, 4). Since the first 
observations in post-mortem examinations of brain of boxers (5), the pathological features 
and clinical correlations of tau neurofibrillary tangle deposition in chronic traumatic 
encephalopathy (CTE) following repetitive TBI have been increasingly well characterized 
(3, 6). However, tau deposition also occurs following a single TBI, after which abundant 
and widely distributed neurofibrillary tangles have been found post-mortem in 
approximately one-third of TBI patients (7). As in Alzheimer’s Disease (AD), all six 
isoforms of tau (including both 3- and 4-repeat isoforms) are observed in post-TBI 
tauopathy (3, 4). However, the distribution of tau pathology after TBI follows a pattern 
distinct from that observed in AD, concentrating primarily in the depths of sulci and at 
points of geometric inflection in the cerebral neocortex, while the medial temporal lobe is 
relatively spared in early disease (7, 3). Although the pathogenic role of TBI as a trigger 
for tau aggregation is not fully understood, traumatic axonal injury appears to lead directly 
to tau hyperphosphorylation (8, 9). 
Flortaucipir ([18F]AV-1451, [18F]T807), a recently developed positron emission 
tomography (PET) radioligand for tau, enables the examination of tau pathology in vivo 
(10, 11). Flortaucipir demonstrated potent and specific non-displaceable binding to tau 
neurofibrillary tangles in post-mortem human brain tissue in AD (12–14). Flortaucipir is 
relatively selective for tau, with no substantial binding to β-amyloid, α-synuclein or TDP-
43 in post-mortem brain tissue (12), although it also binds off-target to monoamine 
oxidases (15) as well as neuromelanin- and melanin-containing cells (12, 16). In vivo, 
flortaucipir binding is increased in AD patients with a regional pattern in keeping with the 
clinical phenotype (17–19), cognitive profile (17, 18) and estimated Braak & Braak staging 
(20). In tau mutation carriers (MAPT gene) and in AD, the distribution of in vivo 
flortaucipir binding and that of post-mortem tau pathology are strongly concordant (19, 
21). Furthermore, in both typical AD and posterior cortical atrophy, flortaucipir binding 
follows the pattern of regional atrophy as quantified by MRI (22, 23).  
A recent report on 26 former National Football League players (24) and a previous 
single case study (25) showed increased cerebral flortaucipir binding following exposure 
to repetitive TBI. However the role of flortaucipir in quantifying tau pathology and its 
distribution in long-term survivors of a single TBI has not been studied. The relationships 
of tau pathology to clinical outcome and biomarkers of neurodegeneration are also unclear. 
Of particular interest is the relationship between tau pathology and white matter 
microstructural changes related to traumatic axonal injury, as these will help to clarify the 
pathophysiological relationship between the initial injury and progressive 
neurodegeneration.  
Here we used flortaucipir PET to study the distribution of tau pathology in 
individuals at least 18 years after a single moderate-severe TBI and in healthy controls.  
TBI participants were primarily recruited from a patient cohort under follow-up at the 
University of Glasgow, who have previously been followed up longitudinally in terms of 
cognitive and disability outcomes (26, 27). We hypothesized that: i) flortaucipir binding 
would be increased in a proportion of participants with TBI many years after their injury; 
ii) flortaucipir binding would correlate with CSF and blood biomarkers of neuronal 
damage and neurodegeneration, including tau; iii) flortaucipir binding would be associated 
with the extent and distribution of diffuse axonal injury, quantified by diffusion MRI and 
voxel-based morphometry (VBM); and iv) flortaucipir binding would be associated with 
poor long-term cognitive outcomes and disability.   
 
 
  
Results  
Participant demographic and clinical characteristics 
21 participants [7 female, 14 male; median age: 49 years (range: 29 to 72)] with a 
history of a single moderate-severe TBI were included in the study. 19 participants with 
TBI were recruited from the Institute of Health and Wellbeing, Head Injury Research 
Group, University of Glasgow, UK, and the remaining 2 (participants P9 and P17 in Table 
1) were recruited from the specialist TBI clinic at Imperial College Healthcare NHS Trust, 
London, UK. Participants were examined at a median time of 32 years (range: 18 to 51 
years) following their injury. TBI was caused by road traffic accidents in 18 participants 
(86%), assault in 2 (10%) and fall from a height in 1 participant (5%). Glasgow Outcome 
Scale – Extended (GOS-E) median score was 6 (range: 4 to 8) at the time of assessment. 
In 15 TBI participants (71%) longitudinal clinical data were also available (27), including 
GOS-E and MMSE scores obtained at a median time point of 16 years (range: 9 to 19 
years) after the injury and 17 years (range: 15 to 19 years) before the current clinical and 
imaging assessment. The demographic and clinical characteristics and APOE genotype of 
individual TBI participants are presented in Table 1. Focal lesions were delineated on MRI 
as specified in the Supplementary Materials. 19 TBI participants (90%) had focal lesions 
apparent on MRI with a median volume of 1634 voxels (range: 12 to 23118 voxels). A 
cerebellar lesion was present on structural MRI in one participant with TBI (P7). There 
were no cerebellar abnormalities on structural MRI in any other participants (fig. S1).  
 
11 healthy controls [5 female, 6 male; median age: 57 years (range: 29 to 72)] of 
similar educational background and estimated premorbid intelligence to the TBI 
participants were also examined. 8 healthy control participants were recruited from the 
Institute of Health and Wellbeing, Head Injury Research Group, University of Glasgow, 
UK, and 3 healthy controls were recruited from the NIHR Imperial Clinical Research 
Facility, London, UK. The demographic characteristics of the TBI and control groups are 
presented in Table 2.  
We divided TBI participants into a good recovery and a disabled subgroup based 
on their Glasgow Outcome Scale – Extended scores (disabled subgroup: GOS-E≤6; good 
recovery subgroup: GOSE>6). Twelve participants [5 female, 7 male; median age: 48.5 
years (range: 39 to 72)] with a median GOS-E of 5 (range: 4 to 6) were included in the 
disabled subgroup and 9 participants with TBI [2 female, 7 male; median age: 54 years 
(range: 29 to 65)] with a median GOS-E of 8 (range: 7 to 8) were included in the good 
recovery subgroup. Longitudinal clinical data were available for 9 participants with TBI 
(75%) in the disabled and 6 participants with TBI (67%) in the good recovery group. The 
demographic characteristics of these subgroups are presented in Table 2. There was no 
significant difference in age or years of education when each of the subgroups was 
compared to healthy controls (disabled TBI vs. healthy controls: age: independent t-test 
t=-0.91, P=0.37; education: Mann-Whitney-Wilcoxon W=60, P=0.73; good recovery TBI 
vs. healthy controls: age: t=-0.93, P=0.36; education: W=64.5, P=0.26). Estimated 
premorbid intelligence (Wechsler Test of Adult Reading, WTAR) was lower in the 
disabled TBI subgroup when compared to healthy controls (W=23, P=0.009), but not 
significantly different between good recovery TBI and healthy controls (W=53.5, P=0.79). 
WTAR score did not correlate with age at injury in either the disabled TBI subgroup or 
the TBI group overall (Spearman ρ=-0.04, P=0.89 and ρ=0.18, P=0.43, respectively). 
 
Neuropsychological performance  
When compared to healthy controls, participants with TBI manifested impairments 
on multiple cognitive domains including processing speed, executive function, motivation, 
inhibition, verbal and visual memory (Table 2), in a neuropsychological profile typical of 
TBI. On most neuropsychological measures, these differences were driven by the disabled 
TBI subgroup (fig. S2). The good recovery TBI subgroup had similar outcomes as healthy 
controls on most measures, with the exception of the Frontal Systems Behavior (FrSBe) 
executive and apathy scores, on which both good recovery and disabled TBI subgroups 
were impaired when compared to healthy controls (good recovery TBI: FrSBe-E: W=74, 
P=0.003; FrSBe-A: W=63.5, P=0.046; disabled TBI: FrSBe-E: W=107.5, P<0.001; 
FrSBe-A: W=94, P=0.005). The good recovery TBI subgroup performed better than the 
disabled subgroup on several cognitive domains including logical reasoning, processing 
speed, executive function, motivation, inhibition, verbal memory, visual memory and 
mood assessment (Table 2). 
As shown in Table 2, there was evidence of cognitive decline on longitudinal 
assessment (average -1.3 MMSE points or -0.073 MMSE points per year) in the disabled 
TBI subgroup whereas the good outcome TBI subgroup showed improvement of cognitive 
performance over time (average 1 MMSE point or 0.058 MMSE points per year), with 
longitudinal change being significantly different between the TBI subgroups (Table 2; 
W=7, P=0.041). 
 
Flortaucipir binding in individual participants with TBI  
To assess flortaucipir binding and its distribution in the brain in individual 
participants with TBI, voxelwise z-scores of MNI registered flortaucipir non-displaceable 
binding potential (BPND) images were derived for each patient versus the healthy control 
group. The resulting z-score maps describe the distribution of flortaucipir in individual 
participants with TBI relative to variations in binding seen in healthy subjects. As 
illustrated in Fig. 1, several participants with TBI had increased flortaucipir binding in a 
patchy cortical and subcortical distribution, involving both grey and white matter (Fig. 1: 
P1 to P8 and P10). In contrast, other participants with TBI had similar flortaucipir BPND 
to that of healthy controls (Fig. 1: P17 to P22).  
 
The number of voxels with high BPND (z>1.645; corresponding to one-tailed 
P<0.05) was used to measure the spatial extent of increased flortaucipir signal in individual 
TBI participants (Fig. 2). Participants with TBI had a median 841 voxels above threshold 
(range: 0 to 15809). For comparison, voxelwise z-scores were also derived for each healthy 
control versus the rest of the control group. In controls, the median number of voxels above 
threshold was 4 (range: 0 to 253; Fig. 2).  
Eight participants with TBI (38%) had >2000 voxels (equivalent to 16 cm3 of brain 
volume) above threshold indicating spatially extensive flortaucipir signal increase, 
whereas a further 7 (33%) showed increased signal of more spatially limited extent (254-
1999 voxels, Fig. 2). The remaining 6 (29%) had less than 253 voxels above threshold, 
falling within the range of the healthy control group. There was no difference in 
flortaucipir spatial extent when comparing between disabled and good functional outcome 
subgroups (Mann-Whitney-Wilcoxon W=68.5, P=0.32). 
 
Reduced flortaucipir binding within focal lesions in TBI 
Flortaucipir binding within focal lesions was significantly reduced when compared 
to non-lesioned cerebral areas (Wilcoxon signed-rank V=22, P=0.002; fig. S3). Areas of 
markedly reduced flortaucipir uptake (in black) in Fig. 1 correspond to focal lesions in 
individual TBI participants (cf fig. S1). Focal lesion size (number of voxels) did not 
correlate with average flortaucipir BPND within the non-lesioned grey or white matter 
(Spearman ρ=-0.37, P=0.10 and ρ=-0.15, P=0.51, respectively; fig. S3), or with flortaucipir 
spatial extent (number of voxels above threshold; ρ=-0.06, P=0.78; fig. S3). 
 
Increased flortaucipir binding in the TBI patient group vs. healthy controls 
Flortaucipir BPND was next compared between TBI and healthy control groups, in 
a non-parametric voxelwise analysis, excluding lesioned areas (fig. S1) and also the 
striatum where off-target binding is observed with this tracer. Flortaucipir binding was 
significantly higher in TBI participants than in healthy controls in the right lateral occipital 
cortex (Fig. 3 inset; P<0.05, adjusted for multiple comparisons). When each of the TBI 
subgroups was independently compared to healthy controls, significantly increased 
flortaucipir binding was found in both TBI subgroups, in the same right lateral occipital 
area (fig. S4; cf. Fig. 3; P<0.05, adjusted for multiple comparisons). There was no 
significant difference in flortaucipir binding when comparing between the disabled (GOS-
E≤6) and good outcome (GOS-E>6) TBI subgroups (fig. S4). There were no areas of 
significantly decreased binding in the TBI group or subgroups compared to healthy 
controls (fig. S4; all P>0.05).  
Additionally, we examined flortaucipir BPND within a medial temporal lobe region 
of interest (ROI) including the entorhinal, perirhinal and parahippocampal cortex and the 
hippocampus, a region typically affected by tau accumulation in Alzheimer’s disease. 
There was no significant difference in flortaucipir binding within this ROI between the 
TBI group, or either of the disabled or good recovery TBI subgroups, and healthy controls 
(fig. S5 Mann-Whitney-Wilcoxon; all TBI vs. healthy controls: W=108, P=0.78; disabled 
TBI vs. healthy controls: W = 57, p-value = 0.61; good recovery TBI vs. healthy controls: 
W=51, P=0.94).   
 
 
Correlations between flortaucipir and CSF T-tau, P-tau and UCH-L1 in TBI 
Next, CSF and plasma biomarkers of neurodegeneration and neuronal damage, 
including total tau (T-tau), tau phosphorylated at amino acid 181 (P-tau), ubiquitin 
carboxy-terminal hydrolase L1 (UCH-L1), β-amyloid 1-42 (Aβ42), neurofilament light 
(NFL), glial fibrillary acidic protein (GFAP) and protein S100 were assessed in TBI and 
healthy controls and their relationship with flortaucipir binding was explored. CSF data 
were available from 19 participants with TBI and 10 healthy controls.  
In TBI, CSF T-tau was significantly correlated with flortaucipir BPND in the 
cerebral cortical grey matter (Spearman ρ=0.53, P=0.022; Fig. 4A), but not in the white 
matter (ρ=0.44, P=0.059; fig. S6). Conversely, CSF P-tau correlated with flortaucipir BPND 
in the cerebral white matter (ρ=0.52, P=0.024; Fig. 4B), but not in the grey matter (ρ=0.32, 
P=0.18; fig. S6). There was no correlation between CSF T-tau or P-tau and flortaucipir 
spatial extent (T-tau: ρ=0.21, P=0.38; P-tau: ρ=0.29, P=0.24; fig. S6). CSF tau in healthy 
controls did not correlate with flortaucipir binding in the cerebral grey matter (T-tau: 
ρ=0.15, P=0.68; P-tau: ρ=-0.21, P=0.56; fig. S6) or white matter (T-tau: ρ=-0.09, P=0.81; 
P-tau: ρ=0, P=1; fig. S6). Plasma T-tau concentration did not correlate with flortaucipir 
binding in either TBI or healthy controls (fig. S6). There were no differences in T-tau or 
P-tau concentration in CSF or plasma between TBI and healthy control groups (CSF T-
tau: W=93, P=0.95; CSF P-tau: W=67, P=0.21; plasma T-tau: W=118, P=0.76; fig. S6).  
UCH-L1 in the CSF in TBI participants also positively correlated with flortaucipir 
BPND in the grey matter (Spearman ρ=0.52, P=0.023; Fig. 4C), but not in the white matter 
(ρ=0.42, P=0.073; fig. S7). There was no association between plasma UCH-L1 and 
flortaucipir binding in TBI (fig. S7). In healthy controls, there were no associations 
between flortaucipir binding and UCH-L1 in the CSF or plasma (fig. S7). There was no 
difference between TBI and control groups in UCH-L1 concentration (fig. S7). There were 
also no associations between flortaucipir BPND and Aβ42, NFL, GFAP or S100 in TBI or 
healthy controls and no difference between TBI and control groups in the CSF or plasma 
(fig. S7).  
 
Flortaucipir spatial extent and white matter damage in TBI 
Next, we investigated the relationship between flortaucipir binding and structural 
brain injury produced by TBI (28). White matter integrity measured by fractional 
anisotropy (FA) was significantly reduced in TBI when compared to healthy controls 
(Mann-Whitney-Wilcoxon W=44, P=0.004; Fig. 5A), in keeping with the presence of 
traumatic axonal injury (TAI) in TBI. As expected in TBI (29), reduced FA correlated with 
worse performance on multiple cognitive measures (table S1). Tissue density measured by 
voxel-based morphometry (VBM) was also significantly reduced in the non-lesioned white 
matter in TBI (W=61, P=0.031; Fig. 5B). Tissue density in the non-lesioned grey matter 
was not significantly different between TBI and healthy control groups (W=113, P=0.94; 
Fig. 5C).  
The spatial extent of flortaucipir binding (number of voxels with BPND z>1.645) 
correlated with the degree of white matter damage seen in TBI participants. The number 
of voxels showing increased flortaucipir binding was negatively correlated with both 
average FA (Spearman ρ=-0.48, P=0.027; Fig. 5D) and average white matter density (ρ=-
0.46, P=0.037; Fig. 5E), in keeping with a relationship between cerebral tau pathology 
with microstructural white matter disruption. There was no significant correlation between 
flortaucipir spatial extent and grey matter tissue density (ρ=-0.31, P=0.17; Fig. 5F). 
 
White matter damage in areas of increased flortaucipir binding 
We next examined whether greater white matter pathology was seen in areas of 
increased flortaucipir binding. As the localisation of increased tau varies from patient to 
patient, we defined areas of high and normal flortaucipir signal (BPND z > or < 1.645) in 
each patient. Eight TBI participants who did not show high flortaucipir signal within the 
white matter were excluded from these analyses. Significantly lower FA (Fig. 6A-B; 
Wilcoxon signed-rank V=19, P=0.018) and white matter density (Fig. 6C-D; V=17, 
P=0.025) was seen in areas of high flortaucipir binding compared to areas where binding 
was not increased, demonstrating relatively high flortaucipir binding in areas of post-
traumatic white matter damage. The corresponding VBM analysis for grey matter density 
did not reveal differences in grey matter density between areas of high and those of normal 
flortaucipir binding (V=97, P=0.95; fig. S8). There was considerable between-subject 
variability in these effects (Fig. 6B and D, fig. S8B).  
 
Cortical flortaucipir binding and white matter microstructural damage 
Next, we examined whether flortaucipir BPND within the right lateral occipital 
cortical area where flortaucipir signal was increased in TBI vs. controls (Fig. 3) was 
associated with white matter tract FA. Increased right lateral occipital flortaucipir binding 
was associated with reduced FA in remote white matter regions, including association, 
commissural and projection tracts (Fig. 7A, B and table S2). Correlations were observed 
in the genu and body of the corpus callosum, as well as in several association tracts within 
the ipsilateral (right) hemisphere, including the cingulum bundle, inferior longitudinal 
fasciculus, uncinate fasciculus and anterior thalamic radiation (Fig. 7B and table S2), but 
not in the contralateral hemisphere (fig. S9 and table S2). Higher cortical flortaucipir BPND 
was associated with reduced tissue density in remote white matter regions including the 
corpus callosum and right prefrontal white matter (Fig. 7C). The same analysis for grey 
matter density did not show an association between flortaucipir BPND within the lateral 
occipital cluster and cerebral cortical grey matter density (P>0.05 corrected for multiple 
comparisons). 
 
Flortaucipir binding and clinical measures in TBI 
There were no correlations of average flortaucipir BPND in the cerebral grey or 
white matter or the spatial extent of high flortaucipir signal in TBI participants (number of 
voxels above BPND z>1.645) with age, time since injury, disability (GOS-E) or any 
neuropsychological measures in the TBI participants (all P>0.05, false discovery rate-
adjusted, table S3).  
 
APOE ε4 genotype interactions with flortaucipir binding and time since injury, 
CSF Aβ42, white matter density and MMSE scores in TBI 
There were no overall differences between participants with at least one APOE ε4 
allele and those without an APOE ε4 allele in either cerebral flortaucipir BPND or in 
flortaucipir spatial extent in the TBI group (Mann-Whitney-Wilcoxon: W=41, P=0.46; 
W=44, P=0.60, respectively; fig. S10).  
In further exploratory analyses, we examined whether APOE carrier status 
(presence of at least one ε4 allele) influenced the relationship between flortaucipir 
measures (average cerebral BPND and spatial extent) and age, time since injury, CSF 
biomarkers, white matter MRI measures, and neuropsychological performance in TBI. 
Interactions between APOE status and each of the above variables on flortaucipir measures 
were examined using linear regression in the TBI group. Interaction plots are presented in 
fig. S11.   
There was an interaction between APOE genotype and time since injury on cerebral 
flortaucipir BPND (F(1,17)=15.11, P=0.001), but not on flortaucipir spatial extent. 
Flortaucipir BPND increased with time elapsed since the TBI in APOE ε4 carriers, but not 
in ε4 non-carriers (fig. S11). Age did not interact with APOE genotype on average cerebral 
flortaucipir BPND or on flortaucipir spatial extent (fig. S11).   
There was an interaction between APOE genotype and CSF Aβ42 on flortaucipir 
BPND (F(1,15)=6.15, P=0.026), but not on flortaucipir spatial extent in TBI (fig. S11). Higher 
cerebral flortaucipir binding was associated with lower Aβ42 concentration in CSF in 
APOE ε4 carriers, but not in ε4 non-carriers (fig. S11). There were no interactions on 
flortaucipir measures between APOE ε4 carrier status and T-tau, P-tau, UCH-L1, NFL, 
GFAP, or S100 CSF concentrations (fig. S11).  
The effect of white matter tissue density (derived from voxel based morphometry) 
on flortaucipir spatial extent was influenced by APOE genotype (F(1,17)=6.90, P=0.018), 
with ε4 non-carriers showing increased flortaucipir binding with reducing white matter 
tissue density, which was not observed in APOE ε4 carriers (fig. S11). There were no 
interactions between white matter tissue density and APOE genotype on average cerebral 
flortaucipir BPND and no interactions between grey matter tissue density or fractional 
anisotropy and APOE genotype on flortaucipir measures (fig. S11).  
APOE genotype influenced the relationship of longitudinal Mini-Mental State 
Exam (MMSE) scores and flortaucipir binding, with decreasing MMSE scores over time 
associated with higher cerebral flortaucipir BPND in ε4 non-carriers, but not in ε4 carriers 
(F(1,10)=40.76, P<0.0001, fig. S11). Current MMSE scores also interacted with APOE ε4 
carrier status on flortaucipir spatial extent, with current MMSE scores being lower with 
increasing spatial extent in ε4 non-carriers, but not in ε4 carriers (F(1,17)=6.14, P=0.024, 
fig. S11.  
 
Similar off-target binding in TBI and healthy controls 
In keeping with the known off-target binding of flortaucipir to neuromelanin (12), 
flortaucipir BPND was increased in the striatum in both TBI participants and in healthy 
controls when compared to the rest of the cerebral white and grey matter, excluding focal 
lesions (Wilcoxon signed-rank TBI: V=214, P=0.0002; controls: V=66, P=0.001; fig. 
S12). However, flortaucipir BPND in the striatum and in the choroid plexus (16) were not 
different between TBI participants and healthy controls (fig. S12).  
 
  
Discussion  
Hyperphosphorylated tau deposition is a key pathological feature of 
neurodegeneration triggered by traumatic brain injury (TBI) (3, 4). Patients are at increased 
risk of Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE) after TBI, 
both characterized by the accumulation of tau pathology (1, 30, 31). Positron emission 
tomography (PET) ligands have recently been developed that specifically bind 
hyperphosphorylated tau, enabling the detection of tau pathology in vivo (32). We used 
flortaucipir PET to investigate tau pathology in a well-characterized cohort of individuals 
who were examined many years after a single moderate-severe TBI (26, 27). As predicted, 
there was considerable variability in the extent of flortaucipir binding across TBI 
participants. Broadly, a third of TBI participants showed extensive increases in cerebral 
flortaucipir binding, a third showed more limited increases and a third showed no 
abnormality. The proportion of individuals with increased flortaucipir binding is much 
higher than would be expected in the general population in this age group (33). At the 
group level, TBI participants showed elevated flortaucipir binding when compared to age- 
and education-matched healthy controls. 
Flortaucipir binds to neurofibrillary tangles containing abnormal tau in post-
mortem human brain tissue in AD (12–14). A lack of specificity has been a critical issue 
with previous PET tau ligands (34), but flortaucipir is more selective and does not show 
substantial β-amyloid, α-synuclein or TDP-43 binding in post-mortem brain tissue (12). 
However, off-target binding to monoamine oxidases and neuromelanin- and melanin-
containing cells is a known limitation (12, 15, 16). Flortaucipir has been validated for the 
study of tau pathology in AD patients, showing binding that correlates with clinical 
phenotype (17–19), cognitive profile (17, 18) and estimated Braak & Braak staging (20). 
Tau pathology seen after TBI appears to be similar to AD, with all six isoforms of tau 
(including both 3- and 4-repeat isoforms) observed (3, 4). As a result, flortaucipir is 
expected to bind tau pathology seen after TBI in a similar way to AD, albeit with a distinct 
spatial pattern (3).  
The pattern of flortaucipir binding potentially provides diagnostic information 
about the type of post-traumatic neurodegeneration. Tau pathology seen after TBI often 
has a distribution distinct from AD. In cases of CTE, tau pathology is concentrated in 
depths of cortical sulci (3, 6) and can be widely distributed in cortical areas following 
single TBI (7). In our study some patients showed extensive flortaucipir binding in cortical 
areas as well as in parts of the white matter. This spatial pattern would be atypical for AD 
(35) but is more in keeping with CTE (3, 4). It is also compatible with the spatially 
extensive tau neurofibrillary tangle pathology seen in approximately one-third of chronic 
TBI patients (7).  
The relationship between tau pathology and flortaucipir binding is supported by 
our CSF results. CSF tau is raised in incipient AD (36) and other tauopathies (37) and 
provides a diagnostic biomarker for AD (38). CSF tau increases in the days after TBI, 
generally falling to normal concentration 8-12 weeks after the injury (39, 40). To our 
knowledge, our study is the first to examine CSF tau several years after moderate-severe 
TBI. CSF T-tau and P-tau were not increased across the TBI group, which might be due 
to the high variability within the TBI group. CSF T-tau and P-tau concentrations correlated 
positively with flortaucipir binding in the cerebral cortex and white matter, respectively, 
supporting the conclusion that increased flortaucipir binding is indicative of the presence 
of tau pathology. We also observed a positive correlation between CSF UCH-L1 
concentration and cortical flortaucipir uptake. In the acute phase, UCH-L1 may indicate 
the presence of neuronal injury following TBI (41). It is abundant in cerebral neurons and 
is an important component of the ubiquitin-proteasome system, (42). Dysfunction of UCH-
L1 is implicated in a number of neurodegenerative diseases (43, 44) and UCH-L1 is found 
within misfolded protein aggregates, including neurofibrillary tangles (45). CSF UCH-L1 
is elevated in patients with Alzheimer disease (46) and our results suggest that the link 
between TBI and dysfunction in the ubiquitin-proteasome system warrants further 
investigation.  
We also showed a relationship between flortaucipir binding and traumatic axonal 
injury (TAI). This is in keeping with a causative role for TAI in the pathophysiology of 
post-traumatic tau pathology. Mechanical forces exerted at the time of head injury are 
thought to disrupt axonal organization producing damage to microtubule structure and 
associated axonal tau (4). This damage may lead to hyperphosphorylation of tau, 
misfolding, and neurofibrillary tangle formation, which eventually causes 
neurodegeneration (8, 9, 47). Mechanical forces are maximal in points of geometric 
inflection such as the base of cortical sulci (48), where tau pathology is seen in CTE.  
In AD, increased flortaucipir binding is greater in cortical regions that show 
atrophy (22, 23). We observed a different relationship following TBI. Flortaucipir binding 
was increased in white matter areas that also showed reduced fractional anisotropy and 
atrophy. This suggests that tau pathology was more marked in areas of TAI. In addition, 
cortical flortaucipir binding also correlated with the extent of TAI within the white matter. 
For example, flortaucipir binding in the right lateral occipital cortex, the most consistent 
area of increase, was correlated with reduced fractional anisotropy in a tract directly 
connected to that cortical area, the inferior longitudinal fasciculus. This relationship might 
be explained by slow Wallerian degeneration that follows the initial injury and leads to the 
accumulation of tau pathology in connected cortical regions (49). Alternatively, prion-like 
spread of tau-pathology might over time result in the cortical accumulation of tau-
pathology in regions that are connected to white matter regions initially damaged by TAI 
(50, 51). We have previously reported a similar relationship between cortical amyloid 
pathology measured using [11C]-PiB PET and the degree of TAI in connected tracts (52), 
suggesting that structural connectivity may influence the neuroanatomical distribution of 
post-traumatic tau and amyloid pathology in similar ways.  
A recent study on former National Football League (NFL) players, exposed to 
repetitive TBI and manifesting cognitive, mood and behavioral symptoms, also found 
raised cerebral flortaucipir binding, which increased with years of exposure to repetitive 
TBI (24). With our results, this supports the hypothesis that the risk for neurodegeneration 
from TBI may be dose-dependent (1), produced either by a single severe TBI or repeated 
exposure to more minor TBI. 
Genetic factors may partially explain the variability in the neurodegenerative 
trajectory following TBI (53, 54). APOE ε4, the strongest risk factor for sporadic AD, is 
associated with increased β-amyloid and tau pathology (55), and it is also the strongest 
genetic predictor of adverse outcome after TBI (56). APOE ε4 may act synergistically with 
TBI to elevate the risk of neurodegeneration (30, 57). Therefore, in exploratory analyses, 
we examined how APOE ε4 carrier status might influence flortaucipir binding. Flortaucipir 
binding increased with time since TBI in APOE ε4 carriers and was associated with lower 
Aβ42 concentrations in the CSF (indicating higher Aβ42 concentrations in the brain) in ε4 
carriers. This supports an influence of APOE ε4 on the risk of neurodegeneration after TBI. 
In keeping with these findings, Aβ plaque pathology following TBI is more prevalent in 
individuals with at least one APOE ε4 allele (57). Results from animal models also support 
the association between APOE ε4 genotype and Aβ pathology after TBI (58).  
Our study has a number of limitations. The relatively small sample size may have 
limited our ability to detect associations between flortaucipir binding and clinical 
outcomes. Hence, the absence of a clinical effect should be interpreted with caution, as our 
study is unlikely to have been adequately powered for these outcomes. In AD, flortaucipir 
uptake was associated with poorer performance in various cognitive domains in regionally 
specific patterns (17). However, the situation is likely to be more complex following TBI 
as the influence of the initial injury on cognitive state will confound progressive 
neurodegenerative effects, resulting in the need for larger sample sizes. Estimated 
premorbid intelligence was lower in the disabled TBI subgroup when compared to healthy 
controls. However, vocabulary development may be adversely affected by TBI during 
development (59). Hence, it is possible that performance on WTAR was directly reduced 
by the TBI, especially in individuals injured during childhood. Flortaucipir binds off-target 
to monoamine oxidases and neuromelanin, which is particularly apparent in the striatum 
and choroid plexus (12, 13, 15, 16). This off-target flortaucipir binding may have limited 
our ability to detect underlying tau pathology in these regions. In addition, a contribution 
from non-tau pathology cannot be excluded with certainty. Flortaucipir binding increases 
have been reported in semantic variant primary progressive aphasia, where the underlying 
pathology is TDP-43 (60), although flortaucipir binding to TDP-43 has not been 
demonstrated post-mortem (12). Off-target binding has also been reported in areas of acute 
parenchymal and subarachnoid haemorrhage, but not in areas showing superficial siderosis 
due to chronic haemorrhage (12). This is unlikely to be a major confound in our study as 
there were no acute haemorrhagic lesions in our participants and binding was reduced 
within focal lesions.  Flortaucipir signal is reduced at the site of focal lesions. Therefore, 
the presence of a focal lesion in one or more TBI participants within a given brain area 
would be expected to reduce our sensitivity in detecting flortaucipir group effects within 
that area. To minimize the impact of lesions in our analysis we took into account the 
location of focal lesions as regressors in voxelwise group comparisons. Finally, brain 
atrophy can impact on PET results, but we employed stringent measures to minimise the 
effects of atrophy during pre-processing. Moreover, the relationship between increased 
flortaucipir binding and reduced white matter tissue density is unlikely to be artifactual, as 
non-specific flortaucipir binding is expected to be reduced within areas of reduced tissue 
density.  
In summary, we show that flortaucipir binding is increased many years after a 
single moderate-severe TBI. Increased binding was associated with CSF indicators of 
neurodegeneration, including T-tau and P-tau, as well as the presence of TAI that may 
provide the initial trigger to its accumulation. The ability to detect tau pathology in vivo 
following TBI has major potential implications for diagnosis and prognostication of 
clinical outcomes after TBI. It is also likely to assist in patient selection and stratification 
for future treatment trials targeting tau.  
  
  
Materials and Methods 
Study design  
This study was designed to assess whether flortaucipir PET provides evidence of 
tau pathology in individuals several years after a single moderate-severe TBI when 
compared to healthy controls. We also examined the relationship of flortaucipir signal with 
CSF and blood biomarkers, MRI measures of axonal injury and cognitive and disability 
outcomes. Imaging assessment and biological sampling was cross-sectional and 
longitudinal cognitive and disability measures were available in a subset of individuals 
with TBI. The sample size was calculated to provide 80% statistical power with a type 1 
error rate of 0.05 to detect an increase in flortaucipir binding in TBI compared to controls, 
based on effect sizes extrapolated from previous flortaucipir data on AD (11), and from 
post-mortem data showing tau pathology in about a third of individuals following 
moderate-severe TBI (7). Investigators performing the PET modeling, MRI processing and 
lesion delineation were blinded as to clinical outcomes and biomarker data. Randomization 
was not applicable in this observational study.  
TBI participants were primarily recruited from two TBI cohorts under follow-up at 
the Institute of Health and Wellbeing, Head Injury Research Group, University of 
Glasgow, UK. The original cohorts included all individuals acutely admitted with TBI to 
the Southern General Hospital, Glasgow, between 1968 and 1985 (27) and between 1996 
and 1999 (26). These individuals have been followed up longitudinally in terms of 
cognitive, wellbeing and disability outcomes (26, 27). Members of these follow-up cohorts 
fulfilling the inclusion criteria for the current study were invited to participate with the 
assent of their general practitioner (primary care physician). Additional TBI participants 
fulfilling the inclusion criteria were recruited from the specialist multidisciplinary TBI 
clinic at Imperial College Healthcare NHS Trust, London, UK. Individuals were recruited 
into the TBI group with the following inclusion criteria: i) a history of a single moderate-
severe TBI (according to Mayo classification (61)), ii) age over 18 years, iii) capacity to 
provide written informed consent, iv) no prior neurological or psychiatric illness, v) no 
contraindication to PET or prior radiation exposure which when combined with the dose 
from the present study would exceed 10 mSv in addition to the natural background 
radiation in the previous 3 years, vi) no contraindication to MRI, vii) no medication use or 
allergies which may compromise participant safety or interfere with study procedures. TBI 
participants were divided into two subgroups based on functional outcome. Poor functional 
outcome was defined as a GOS-E score of 6 or less (moderate-severe disability) at the time 
of assessment and those with GOS-E greater than 6 as good outcome. Healthy volunteers 
of similar age and socioeconomic background as the TBI participants were also recruited. 
The study was approved by the Westminster Research Ethics Committee and the 
Administration of Radioactive Substances Advisory Committee. All participants gave 
written informed consent. 
 
Procedures 
All participants were administered an IV bolus of flortaucipir (also known as 
[18F]AV-1451 and [18F]T807), average dose 250 MBq and dynamic PET scans were 
acquired over 90 minutes. Flortaucipir was supplied by Avid Radiopharmaceuticals, a 
wholly owned subsidiary of Eli Lilly and Company and PET image acquisition was carried 
out at Imanova Centre for Imaging Sciences (currently Invicro London). Flortaucipir PET 
data was analyzed with the Molecular Imaging and Kinetic Analysis Toolbox (MIAKAT 
www.miakat.org) using the simplified reference tissue model (SRTM) (62, 63)  with 
cerebellar grey matter as the reference tissue, based on post-mortem studies in chronic 
traumatic encephalopathy which demonstrated relative sparing from tau pathology in that 
region (3, 64). All participants also underwent structural 3T MRI, including volumetric T1 
and diffusion tensor imaging (DTI). Details on PET and MRI acquisition and analyses are 
provided in Supplementary Materials. 
TBI and control participants took part in neuropsychological assessment and had venous 
blood and cerebrospinal fluid (CSF) sampling. Clinical assessment, blood and CSF sample 
acquisition were carried out at the NIHR/Welcome Trust Imperial Clinical Research 
Facility. Details on neuropsychological assessments and biological sample analyses are 
provided in Supplementary Materials. 
 
 
Statistical analyses 
Statistical analyses were carried out using R statistical software (www.r-
project.org) (65) unless specified otherwise.  
Voxelwise differences in BPND between TBI participants and healthy controls, 
between each of the disabled TBI and good recovery TBI subgroups and healthy controls 
as well as between these subgroups were assessed using permutation tests in FSL (66). The 
same procedure was used to assess voxelwise differences between TBI participants and 
healthy controls in: i) VBM-derived white matter density ii) grey matter density and iii) 
diffusion MRI-derived skeletonized fractional anisotropy (FA). Voxels corresponding to 
structural lesions were excluded from the analyses by using subjects’ lesion maps as 
individual voxelwise repressors. All cerebral grey and white matter voxels were included 
except those corresponding to the striatum, where there is known off-target binding (12). 
1000 permutations were used and results were cluster-corrected for multiple comparisons 
using threshold-free cluster enhancement (TFCE) and a family-wise error rate of 0.05. 
Localisation of  voxel clusters was reported based on the Harvard-Oxford probabilistic 
atlas (67) and the JHU DTI-based white matter atlas (68). 
To investigate whether white matter tau pathology shared common localisation 
with traumatic axonal injury and / or white matter atrophy in TBI, we compared 
skeletonized FA and, separately, average white matter density (z-scores) within areas of 
high flortaucipir signal (BPND z>1.645) versus white matter areas where binding was not 
increased (BPND z<1.645) using (paired) Wilcoxon signed-rank tests. Any voxels 
corresponding to focal lesions were excluded. Only TBI participants with 15 or more white 
matter voxels with increased flortaucipir binding within the regions of interest were 
included.  
To examine the localisation of white matter microstructural damage predicted by 
increased flortaucipir cortical signal in TBI participants, standardized BPND within the 
right parietal cortical area of flortaucipir increase in TBI was used as a regressor in a 
voxelwise GLM of skeletonised FA, and separately, in a voxelwise GLM of white matter 
density. Statistical significance was tested using permutation tests in FSL (66). As 
previously, voxels corresponding to lesions were excluded for each individual, 1000 
permutations were used and results were obtained using TFCE, corrected for multiple 
comparisons using a family-wise error rate of 0.05. Localisation of voxel clusters was 
reported based on the JHU DTI-based white matter atlas (68). Post-hoc correlations were 
examined using Spearman’s rank correlation between standardized BPND within the right 
parietal cortical area of flortaucipir increase in TBI participants and skeletonized FA in the 
following tracts: right and left superior longitudinal, inferior longitudinal, inferior fronto-
occipital fasciculi and cingulum bundles, corpus callosum (genu, body and splenium) as 
well as in the right and left corticospinal tracts as a control.   
Correlations between clinical/neuropsychological measures and PET markers in 
TBI participants were examined using Spearman’s rank correlation with false discovery 
rate (FDR) correction for multiple comparisons. Interactions between APOE genotype 
(presence of at least one ε4 allele) and age, time since injury, CSF biomarkers, white matter 
MRI measures, and neuropsychological performance on cerebral flortaucipir BPND and 
flortaucipir spatial extent were examined in the TBI group using linear regression in each 
case to assess the statistical significance of the interaction term, and interaction plots to 
determine the direction of the effect in ε4 carriers vs non-carriers. Assumptions of multiple 
linear regression analysis were tested as follows: analysis of standard residuals was carried 
out to identify outliers; variance inflation factor was used to test for multicollinearity; 
Durbin-Watson test was conducted to test for independence of errors; approximate normal 
distribution of errors, homoscedacity and linearity were assessed by plotting regression 
standardized residuals. 
 
Additional Materials and Methods are provided in the Supplementary Materials. 
  
 Supplementary Materials 
Materials and Methods 
Fig. S1. Focal lesions in TBI participants.  
Fig. S2: Individual data points as well as means and standard deviations for demographic 
and neuropsychological results in the healthy control group (HC), disabled TBI subgroup 
(TBI-D) and good recovery TBI subgroup (TBI-G). 
Fig. S3: Flortaucipir binding and focal lesions. A) Reduced flortaucipir BPND within focal 
lesions compared to non-lesioned cerebral areas. No correlation between lesion size 
(number of lesioned voxels) and B) grey matter (GM), or C) white matter (WM) average 
flortaucipir BPND, or D) flortaucipir spatial extent. 
Fig. S4: Voxelwise comparisons between subgroups in flortaucipir binding. 
Fig. S5: Flortaucipir medial temporal lobe BPND in the in the healthy control (HC), 
disabled TBI (TBI-D) and good recovery TBI (TBI-G) groups. 
Fig. S6: Relationships of CSF T-tau and P-tau and plasma T-tau concentrations with 
flortaucipir (FTP) grey matter (GM) BPND, white matter (WM) BPND  and spatial extent in 
TBI and healthy controls. 
Fig. S7: Relationships of CSF and plasma UCH-L1, NFL, GFAP, S100 and CSF Aβ42 
with cerebral grey matter (GM) and white matter (WM) flortaucipir BPND in TBI and 
healthy controls. 
Table S1. Correlations between neuropsychological measures and average white matter 
tract fractional anisotropy in TBI. 
Fig. S8: Grey matter density within areas of increased flortaucipir BPND in TBI. 
Fig. S9: Flortaucipir right parietal cluster (TBI>Control) BPND (z-score compared to 
healthy controls) and fractional anisotropy (FA) in white matter tracts in TBI. 
Table S2. Correlations between Flortaucipir right parietal cluster (TBI>Control) BPND (z-
score compared to healthy controls) and fractional anisotropy (FA) in white matter tracts 
in TBI participants. 
Table S3. Correlations between clinical measures and each of: flortaucipir right parietal 
cluster (TBI>Control) BPND, whole cerebral cortex BPND (z-score compared to the healthy 
control group), white matter BPND (z-score compared to the healthy control group) and 
spatial extent (N of voxels with BPND z-score>1.645 of healthy controls) in TBI 
participants.  
Fig. S10: No difference in flortaucipir BPND (z-score compared to healthy controls) or 
spatial extent (number of voxels above threshold) in TBI when comparing individuals with 
at least one APOE ε4 allele and those not carrying an ε4 allele. 
Fig. S11: Interactions between APOE genotype and each of time since injury, age, CSF T-
tau, P- tau, Aβ42, NFL, GFAP, S100 concentrations, white matter (WM) and grey matter 
(GM) densities and MMSE scores (longitudinal change and current) on Flortaucipir BPND 
(z-score compared to controls and spatial extent (N voxels above threshold) in TBI. 
Fig. S12: Off-target flortaucipir binding in the striatum and choroid plexus compared to 
other cerebral areas in healthy controls and TBI. 
Fig. S13. Flortaucipir reference region time activity curves (TAC).  
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Tables 
 
Table 1 
Patient Age Sex 
TBI 
etiology 
Time since 
TBI (years) 
GOS-E 
current 
(change) 
MMSE 
current 
(change) APOE 
P1 56 Female RTA 35 5 (0) 22 (-2) ε3/ε3 
P2 39 Female RTA 28 5 (-1) 27 (-2) ε3/ε3 
P3 61 Female RTA 35 5 (-1) 28 (-2) ε3/ε3 
P4 39 Male RTA 32 4 (0) 28 (-1) ε3/ε4 
P5 57 Male RTA 35 8 (0) 30 (0) ε3/ε4 
P6 54 Female RTA 36 5 (-3) 27 (2) ε3/ε4 
P7 65 Male Fall 31 7 (0) 30 (2) ε3/ε4 
P8 29 Female RTA 18 7 (NA) 29 (NA) ε3/ε3 
P9 49 Male RTA 27 5 (NA) 28 (NA) ε2/ε3 
P10 48 Male RTA 37 6 (-2) 29 (-1) ε3/ε3 
P11 46 Female RTA 31 8 (0) 29 (0) ε3/ε3 
P12 44 Male RTA 29 6 (-1) 24 (-2) ε3/ε3 
P13 54 Male RTA 32 7 (0) 29 (NA) ε3/ε3 
P14 57 Male RTA 37 8 (0) 30 (3) ε3/ε3 
P15 54 Male RTA 34 5 (-1) 29 (2) ε3/ε4 
P16 38 Male RTA 19 8 (NA) 29 (NA) ε3/ε3 
P17 72 Male Assault 51 5 (NA) 27 (NA) ε3/ε3 
P18 40 Female RTA 31 5 (0) 23 (-6) ε3/ε4 
P19 43 Male RTA 35 8 (0) 30 (0) ε3/ε3 
P20 55 Male Assault 20 8 (NA) 30 (NA) ε3/ε4 
P21 43 Male RTA 20 5 (NA) 26 (NA) ε4/ε4 
Abbreviations: APOE: apolipoprotein E genotype; GOS-E = Glasgow Outcome Scale Extended; 
MMSE = Mini-Mental State Examination; NA = not available; RTA = road traffic accident; TBI = 
traumatic brain injury. 
 
Table 1: Clinical characteristics of individual TBI participants. Participant 
designations correspond to those in Figures 1, 2 and S1. 
  
Table 2 
 
Outcome measure TBI vs. Healthy participants Disabled vs. Good recovery TBI subgroups 
 TBI 
mean (+/- SD)  
Controls 
mean (+/- SD)  
W  P Disabled TBI 
subgroup 
mean (+/- SD)  
Good recovery TBI 
subgroup 
mean (+/- SD)  
W  P 
Age (years)  49.7 (10.3) 54.2 (12.1) 80 0.16 49.9 (10) 49.3 (11.2) 35 0.29 
Time since injury (years)  31.1 (7.6) - - - 32.9 (7.4) 28.7 (7.5) 66.5 0.39 
Education (years)  12.5 (3.6) 11.5 (2.8)  124.5 0.73 11.5 (3.2) 13.9 (3.8) 33.5 0.15 
Premorbid intelligence WTAR (scaled) 101.4 (16.4) 110.3 (10.8) 76.5 0.13 92.6 (16.1) 113.1 (6.8) 9.5 0.002 
Cognitive impairment MMSE (current) 27.8 (2.3) 29.5 (0.9) 57.5 0.017 26.5 (2.3) 29.6 (0.5) 4 <0.001 
MMSE (change) -0.5 (2.3) - - - -1.3 (2.4) 1 (1.4) 7 0.041 
MMSE (change per year) -0.026 (0.131) - - - -0.073 (0.134) 0.058 (0.081) 7 0.045 
Logical reasoning WASI Matrix Reasoning  22.7 (8.2) 25.2 (7) 87 0.46 18.1 (7.3) 28.9 (4.4) 8.5  0.001 
Processing speed 
 
Trail Making Test A (s) 39.9 (20.6) 28.9 (14.4) 153 0.079 49.7 (22.9) 27.9 (7.6) 81 0.016 
Trail Making Test B (s) 106.8 (69.8) 57.4 (18.3) 158 0.049 140.8 (75.3) 65.2 (30.6) 81 0.016 
Stroop Combined Baseline (s) 50.8 (10.8) 41.1 (8.5) 175 0.017 52.7 (12.3) 48.2 (8.6) 67 0.38 
CRT RT (ms) 579 (121) 512 (103) 160.5 0.077 645 (115) 491 (53) 94 0.003 
Executive function Trail Making Test B-A (s) 66.9 (56) 28.5 (8.7) 145 0.15 91.1 (63) 37.3 (26.3) 79  0.028 
Stroop Inhibition-Switch(s) 93 (48.7) 65.3 (20.4) 164 0.056 116.4 (52.7) 61.9 (14.2) 100 <0.001 
Stroop Inhibition-Switch vs. 
Baseline (s)  
71.4 (50.7) 51.8 (18.9) 145 0.25 94.6 (54.5) 40.42 (21.2) 96 0.002 
FrSBe-Executive; current 42.2 (8.2) 26.3 (5.7) 181.5 <0.001 46 (8.2) 37.1 (4.9) 89.5 0.012 
Apathy  LARS  -21.5 (10.1) -27.2 (6.3) 134 0.14 -17.2 (10.7) -27.9 (4.5) 82 0.009 
FrSBe-Apathy; current 31.9 (9.6) 21 (5.1) 157.5 0.005 34.3 (10.5) 28.8 (7.8) 71 0.24 
Impulsivity / Disinhibition BIS  66.6 (15.8) 58.1 (6.9) 118.5 0.29 72.9 (15) 57.9 (13.2) 75 0.039 
FrSBe-Disinhibition; current 33.5 (10.3) 24.3 (5.3) 143.5  0.028 36.1 (11.5) 30.1 (7.7) 70.5 0.25 
Verbal memory PT Immediate Recall  18.3 (8.7) 19.8 (8.2) 102 0.61 16.4 (9.2) 20.4 (7.8) 39.5 0.32 
PT Delayed Recall 6.4 (3.8) 7.3 (3.6) 100.5 0.56 5.6 (3.9) 7.6 (3.5) 38.5 0.28 
HVLT Immediate Recall  21.2 (5.3) 25.5 (4.7) 63 0.038 19.4 (4.9) 23.7 (5) 25.5 0.046 
HVLT Delayed Recall 6.3 (3.6) 8.8 (2.5) 65.5 0.048 5.3 (3.9) 7.7 (2.7) 34 0.16 
HVLT RDI 9.2 (2.4) 9.9 (2) 97 0.47 8.7 (2.8) 10 (1.5) 40 0.33 
Visual memory Paired Associates Learning (z-
score) 
-1.47 (0.81) -0.73 (0.92) 66 0.043 -1.79 (0.77) -1.03 (0.69) 25.5 0.036 
BVMT Immediate Recall  16.2 (8.3) 21.7 (5.5) 63 0.039 10.9 (3.7) 23.3 (7.5) 7 <0.001 
BVMT Delayed Recall 6.8 (3.7) 9.5 (1.4) 64.5 0.044 4.7 (3.1) 9.6 (2.4) 12 0.003 
BVMT RDI 4.9 (1.3) 5.9 (0.3) 67.5 0.026 4.3 (1.4) 5.9 (0.3) 16 0.004 
Visuospatial ability Feature match test (z-score) -1.46 (0.74) -1.19 (0.92) 94.5 0.42 -1.88 (0.69) -0.89 (0.31) 6  <0.001 
Mood disturbance HADS-Anxiety 8 (6) 3.9 (3.8) 161.5 0.069 9.9 (5.6) 5.3 (5.7) 80.5 0.063 
HADS-Depression 4.5 (4.7) 1.9 (2.5) 156 0.11 6.4 (5.1) 1.8 (2.4) 86.5 0.022 
Abbreviations: BIS = Barratt Impulsivity Scale; BVMT = Brief Visuospatial Memory Test; CRT = Choice reaction time; PT = People’s Test; FrSBe = Frontal Systems Behavior 
Scale; HADS = Hospital Anxiety and Depression Score; HVLT = Hopkins Verbal Learning Test; LARS = Lille Apathy Rating Scale; MMSE = Mini-mental State Examination; 
ms = milliseconds; RDI = Recognition Discrimination Index; RT = Reaction time; s = seconds; SD = Standard deviation; WASI = Wechsler Abbreviated Scale for Intelligence; 
WTAR = Wechsler Test of Adult Reading. 
 
Table 2: Demographic and neuropsychological comparisons between TBI and healthy control groups, as well as between disabled 
TBI and good recovery TBI subgroups. Independent sample Mann-Whitney-Wilcoxon test W and P-values (P<0.05 in bold) for 
comparisons between groups and subgroups. 
Figures 
 
Fig. 1: Flortaucipir BPND z-score maps for each TBI individual are compared 
voxelwise to healthy controls. TBI participants are presented in descending order of 
number of voxels with flortaucipir BPND z>1.645 (see Fig. 2). Axial images are displayed 
in radiological convention at MNI coordinate 55. Patchy cortical and subcortical increase 
in tracer uptake is observed in some TBI participants, most consistently in the lateral 
occipital cortex (P1 to P8 and P10), whereas others show similar BPND values as controls 
(P17 to P21). The corresponding clinical characteristics are presented in Table 1. 
Participant designations correspond to those in Table 1, Figure 2 and fig. S1. 
  
 
Fig. 2: The spatial extent of increased flortaucipir binding in TBI is expressed as the 
number of voxels with flortaucipir BPND z>1.645 for each TBI patient compared to 
the healthy control group. The dotted line represents the number of voxels above 
threshold in the healthy control subject with the maximum number of voxels above that 
threshold (compared to the rest of the controls). Participant designations correspond to 
those in Table 1, Figure 1 and fig. S1. The inset figure shows the number of voxels above 
threshold (in logarithmic scale) in TBI and healthy controls.  
 
 Fig. 3: Flortaucipir BPND is increased in TBI compared to healthy controls. Voxels 
with increased flortaucipir uptake in TBI at P<0.05, not adjusted for multiple comparisons, 
are shown on axial slices for illustration. Flortaucipir binding was increased in TBI in a 
small cluster of voxels in the right parietal cortex (inset, P<0.05, corrected for multiple 
comparisons).  
 
 
Fig. 4: Flortaucipir binding is associated with CSF biomarkers in TBI. CSF total tau 
(T-tau, A), phosphorylated (P-tau, B) and UCH-L1 (C) concentrations in the CSF are 
positively correlated with flortaucipir BPND (normalized against the healthy control group) 
in the cerebral grey matter (T-tau, UCH-L1) and in the cerebral white matter (P-tau) in 
TBI participants.  
 
 Fig. 5: White matter microstructural changes in TBI are associated with flortaucipir 
spatial extent. A) Cerebral white matter fractional anisotropy (FA) and B) VBM-derived 
white matter tissue density are reduced in TBI when compared to healthy controls (HC). 
This was not observed with grey matter tissue density (C). Flortaucipir spatial extent 
(number of voxels above threshold) in TBI is associated with reduced white matter FA (D) 
and white matter tissue density (E), but not with grey matter tissue density (F). **P<0.005, 
*P<0.05. 
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 Fig. 6: Increased white matter flortaucipir BPND co-localizes with white matter 
microstructural changes in TBI. Skeletonized FA (A) and white matter density (C), 
standardized against controls, were compared within subject between areas of increased 
flortaucipir binding (in red) and areas where binding was not increased (in blue). A 
representative axial slice for each patient shows the spatial distribution of the white matter 
areas compared and images are presented in order of greatest to smallest effect size 
(greatest decrease in FA or white matter density z-score in high flortaucipir areas shown 
top left). Both FA z-scores (B) and white matter density z-scores (D) are lower within areas 
of increased flortaucipir binding, defined as BPND Z > 1.645. 
 
 Fig. 7: Increased cortical flortaucipir binding in the right lateral occipital area is 
associated with microstructural white matter damage in TBI. A) Increased flortaucipir 
BPND in the right lateral occipital cortex in TBI participants was associated with reduced 
cal PF
R ATR
diffusion MRI-derived fractional anisotropy (FA) in remote white matter tracts (upper 
panel), partly overlapping with white matter tracts of reduced FA in TBI when compared 
to controls (lower panel). B) Flortaucipir BPND in the right lateral occipital cortex in TBI 
participants correlated negatively with average skeletonized FA within the genu and body 
of the corpus callosum as well as within the cingulum bundle, inferior longitudinal 
fasciculus (ILF), anterior thalamic radiation (ATR) and uncinate fasciculus in the right 
hemisphere. Correlation coefficients and P-values presented in Table S2. C) Upper panel: 
increased flortaucipir BPND in the right lateral occipital cortex in TBI participants is 
associated with reduced voxel-based morphometry-derived white matter density in the 
corpus callosum (cal) and right prefrontal area (PF). This distribution partly overlaps with 
areas of white matter atrophy in TBI when compared to controls (lower panel). Results 
presented in radiological convention, color maps represent P values <0.05 adjusted for 
multiple comparisons. 
 
 
 
